Trial · NCT02466971
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) Rate at 3 Years | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | 78.1 | 95% Confidence Interval 70 to 84 | percentage of participants | |
| Overall Survival (OS) Rate at 3 Years | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | 79.6 | 95% Confidence Interval 72 to 85 | percentage of participants | |
| Progression-free Survival (PFS) Rate at 3 Years | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | 69.5 | 95% Confidence Interval 62 to 76 | percentage of participants | |
| Progression-free Survival (PFS) Rate at 3 Years | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | 71.4 | 95% Confidence Interval 64 to 78 | percentage of participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | Anemia | 23 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | Anemia | 18 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | Other blood and lymphatic system disorders | 5 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | Other blood and lymphatic system disorders | 7 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | White blood cell count decreased | 19 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | White blood cell count decreased | 17 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | Platelet count decreased | 5 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | Platelet count decreased | 2 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | Neutrophil count decreased | 13 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | Neutrophil count decreased | 4 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | Other investigations | 39 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | Other investigations | 41 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | Cardiac disorders | 0 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | Cardiac disorders | 2 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm I (Cisplatin, IMRT or RT, Brachytherapy) | Eye disorders | 0 | Participants | |
| Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period | Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine) | Eye disorders | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02466971/results